DelveInsight’s, “Antibody Drug Conjugate Competitive landscape, 2025,” report provides comprehensive insights about 180+ companies and 290+ drugs in Antibody Drug Conjugate Competitive landscape. It covers the Antibody Drug Conjugate therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive ADC pipeline products in this space.
Explore the full insights into the evolving Antibody Drug Conjugate Pipeline and discover which companies are leading the innovation race @ Antibody Drug Conjugate Competitive Landscape Report
Key Takeaways from the Antibody Drug Conjugate Competitive Landscape Report
- On 22 August 2025, GlaxoSmithKline announced a study researchers are testing GSK5764227, a new medicine that targets specific proteins (B7-H3) on cancer cells, thereby reducing the cancers ability to grow and spread. This study specifically aims to evaluate how well GSK5764227 works in treating relapsed SCLC compared to standard treatment topotecan, by checking whether GSK5764227 makes cancers smaller or disappear completely and if it helps participants live longer. The study is also assessing whether GSK576227 is safe and tolerated well by participants compared to topotecan and provide a better understanding of the main side effects of both drugs. Participants with relapsed SCLC will be randomly divided into two groups: one group receiving GSK5764227 and the other receiving topotecan.
- On 20 August 2025, Alentis Therapeutics AG conducted a study is to evaluate the safety, tolerability, pharmacokinetic, pharmacodynamic, preliminary anti-tumor activity, and to determine the recommended Phase II dose (RP2D) of the ALE.P02 monotherapy in adult patients with selected squamous solid tumors.
- DelveInsight’s Antibody Drug Conjugate competitive landscape report depicts a robust space with 180+ active players working to develop 290+ pipeline therapies for Antibody Drug Conjugate treatment.
- The leading Antibody Drug Conjugate Companies such as NBE-Therapeutics, ImmunoGen, Inc., Seagen Inc., ADC Therapeutics, Mythic Therapeutics, Sutro Biopharma, Merck KGaA, Sorrento Therapeutics, Inc., Peak Bio, Regeneron Pharmaceuticals, Asana BioSciences, Tanabe Research Laboratories USA, OBI Pharma, Sanofi, and Navrogen, and others.
- Promising Antibody Drug Conjugate Pipeline Therapies such as Sacituzumab govitecan, STI-6129, Taxotere (docetaxel), DS-8201a, REGN5093-M114, Cemiplimab, Sacituzumab Govitecan-hziy, M9140, Talazoparib, LCB84 and others.
Unlock detailed analysis of the Antibody Drug Conjugate Competitive Landscape 2025 and identify key growth opportunities @ Antibody Drug Conjugate Research and Development Report
Antibody Drug Conjugate Marketed Therapies
- Pfizer
Pfizer Oncology is committed to pursuing innovative treatments that have a meaningful impact on those living with cancer. As a leader in oncology speeding cures and accessible breakthrough medicines to patients, Pfizer Oncology is helping to redefine life with cancer. The strong pipeline of biologics, small molecules and immunotherapies, one of the most robust in the industry, is studied with precise focus on identifying and translating the best scientific breakthroughs into clinical application for patients across a wide range of cancers. By working collaboratively with academic institutions, individual researchers, cooperative research groups, governments and licensing partners, Pfizer Oncology strives to cure or control cancer with its breakthrough medicines. Because Pfizer Oncology knows that success in oncology is not measured solely by the medicines you manufacture, but rather by the meaningful partnerships you make to have a more positive impact on people’s live.
- MYLOTARG
MYLOTARG is an antibody-drug conjugate (ADC) composed of the cytotoxic agent calicheamicin, attached to a monoclonal antibody (mAB) targeting CD33, an antigen expressed on the surface of myeloblasts in up to 90 percent of AML patients. When MYLOTARG binds to the CD33 antigen on the cell surface it is absorbed into the cell and calicheamicin is released causing cell death. MYLOTARG was approved by the U.S. Food and Drug Administration in September 2017 for adults with newly diagnosed CD33-positive acute myeloid leukemia (AML), and adults and children 2 years and older with relapsed or refractory CD33-positive AML. MYLOTARG originates from a collaboration between Pfizer and Celltech, now UCB. Pfizer has sole responsibility for all manufacturing, clinical development and commercialization activities for this molecule. Pfizer also collaborated with SFJ Pharmaceuticals Group on the registrational program for MYLOTARG.
- AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. The Company’s focus is on some of the most challenging cancers. It is through persistent innovation that AstraZeneca has built one of the most diverse portfolios and pipelines in the industry, with the potential to catalyse changes in the practice of medicine and transform the patient experience. Daiichi Sankyo Company, Limited and AstraZeneca entered into a global collaboration to jointly develop and commercialise Enhertu (a HER2-directed ADC) in March 2019, and datopotamab deruxtecan (DS-1062; a TROP2-directed ADC) in July 2020, except in Japan where Daiichi Sankyo maintains exclusive rights. Daiichi Sankyo is responsible for manufacturing and supply of Enhertu and datopotamab deruxtecan. Building on the first approval of Enhertu, a HER2-directed ADC, in previously treated HER2-positive metastatic breast cancer, AstraZeneca and Daiichi Sankyo are exploring its potential in earlier lines of treatment and in new breast cancer settings.
- Enhertu
Enhertu is a HER2-directed ADC. Designed using Daiichi Sankyo’s proprietary DXd ADC technology, Enhertu is the lead ADC in the oncology portfolio of Daiichi Sankyo and the most advanced programme in AstraZeneca’s ADC scientific platform. Enhertu consists of a HER2 monoclonal antibody attached to a topoisomerase I inhibitor payload, an exatecan derivative, via a stable tetrapeptide-based cleavable linker. Enhertu (5.4mg/kg) is approved in more than 40 countries for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received a (or one or more) prior anti-HER2-based regimen, either in the metastatic setting or in the neoadjuvant or adjuvant setting, and have developed disease recurrence during or within six months of completing therapy based on the results from the DESTINY-Breast03 trial. Enhertu (5.4mg/kg) is approved in more than 30 countries for the treatment of adult patients with unresectable or metastatic HER2-low (immunohistochemistry [IHC] 1+ or IHC 2+/in-situ hybridisation [ISH]-) breast cancer who have received a prior systemic therapy in the metastatic setting or developed disease recurrence during or within six months of completing adjuvant chemotherapy based on the results from the DESTINY-Breast04 trial. Enhertu (5.4mg/kg) is approved under accelerated approval in the US for the treatment of adult patients with unresectable or metastatic non-small cell lung cancer whose tumours have activating HER2 (ERBB2) mutations, as detected by an FDA-approved test, and who have received a prior systemic therapy based on the results from the DESTINY-Lung02 trial. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. Enhertu (6.4mg/kg) is approved in more than 30 countries for the treatment of adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma who have received a prior trastuzumab-based regimen based on the results from the DESTINY-Gastric01 trial and/or DESTINY-Gastric02 trial.
Antibody Drug Conjugate Pipeline Therapies and Company
- Jiangsu Hengrui Medicine Co Ltd.
Jiangsu Hengrui Medicine Co Ltd (Jiangsu Hengrui) is a biopharmaceutical company that focuses on the research, development, manufacture, and distribution of novel pharmaceutical products. Its product portfolio includes anti-tumor drugs, surgical drugs, contrast agents, angiomyocardiac drugs, and antibiotics. The company is also developing pipeline products for the treatment of cancer, Crohn’s disease, anemia, diabetes, atopic dermatitis, chronic bone disease, blood pressure, and hypercholesterolemia. Jiangsu Hengrui has R&D facilities in China, the US, and Japan. The company offers products through its sales and distribution network in China, the US, Japan, Germany Switzerland, and Australia. Jiangsu Hengrui is headquartered in Lianyungang, Jiangsu Province, China.
- SHR-A1811
SHR-A1811 is an innovative HER2-targeted antibody-drug conjugate with a topoisomerase I payload conjugated to an anti-HER-2 mAb by a cleavable linker. Once bound to HER2 expressing tumor cells, the ADC is internalized and the linker releases the toxin, leading to tumor cell death. It can bind to the cell membrane surface of HER2 expressing cells, and then enter the cells to reach the lysosome to release small Molecular toxins eventually induce tumor cell apoptosis, combining the high targeting of antibodies and the powerful killing power of cytotoxic drugs on target cells.
Preclinical research results show that SHR-A1811 has good anti-tumor activity, safety, tolerability and pharmacokinetic characteristics, or can further improve drug resistance, enhance efficacy, meet clinical needs, and provide more cancer patients multiple choice. Currently, the drug is in the Phase III stage of its development for the treatment of HER2 positive breast cancer. The drug is also being evaluated for the treatment of gynaecological cancer, gastric cancer, non-small cell lung cancer, oesophageal cancer, and solid tumors.
- Seagen Inc.
Seagen, formerly Seattle Genetics, is a biotechnology company that discovers, develops, and markets monoclonal antibody-based therapies for the treatment of cancer. It markets antibody-drug conjugates (ADCs), including Adcetris (brentuximab vedotin), for the treatment of Hodgkin’s lymphoma, T-cell lymphomas and CD30-expressing lymphomas; Padcevtm (enfortumab vedotin-ejfv) for metastatic urothelial cancers; Tukysa (tucatinib) for the treatment of metastatic HER2-positive breast cancers, and Tivdak (tisotumab vedotin-tftv) for the treatment of certain metastatic cervical cancers. The company’s pipeline consists of novel therapies for addressing the unmet medical needs of blood-related cancers and solid tumors. Seagen products and pipeline are based on ADC technology, which targets monoclonal antibodies and delivers agents for killing cancer cells. The company sells its products through specialty distributors. Seagen is headquartered in Bothell, Washington, the US.
- Ladiratuzumab Vedotin
Ladiratuzumab vedotin is a novel investigational ADC targeted to LIV-1. Most metastatic breast cancers express LIV-1, which also has been detected in several other cancers, including lung, head and neck, esophageal and gastric. Ladiratuzumab vedotin utilizes Seattle Genetics’ proprietary ADC technology and consists of a LIV-1-targeted monoclonal antibody linked to a potent microtubule-disrupting agent, monomethyl auristatin E (MMAE) by a protease-cleavable linker. This novel ADC is designed to bind to LIV-1 on cancer cells and release the cell-killing agent into target cells upon internalization. Ladiratuzumab vedotin may also cause antitumor activity through other mechanisms, including activation of an immune response by induction of immunogenic cell death. Currently the drug is in Phase II stage of Clinical trial evaluation for the treatment of Unresectable Locally Advanced or Metastatic Solid Tumors.
- ImmunoGen, Inc.
ImmunoGen is developing the next generation of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, ImmunoGen, Inc. aim to disrupt the progression of cancer and offer the patients more good days. ImmunoGen, Inc. believe ADCs have a promising and durable role in cancer care. This belief has driven the work for over four decades. It’s what has led to the leadership position in the ADC field, and it’s why everything ImmunoGen, Inc. do is about developing the most precise, targeted cancer therapies.
- IMGN151
IMGN151 is a next-generation Antibody-drug Conjugate designed to address the unmet needs of cancer patients with tumor types expressing lower levels of folate receptor alpha (FRα). The investigational drug comprises an asymmetric, bivalent, biparatopic antibody targeting two independent epitopes of FRα, linked to a highly potent maytansinoid derivative, DM21, via a cleavable peptide linker with enhanced stability, longer half-life, and increased bystander activity. IMGN151 activity was characterized against cell lines and xenograft models with a wide range of FRα expression and compared to IMGN853. In in vitro studies, both IMGN151 and mirvetuximab soravtansine had similar activity against FRα-high KB cells. However, IMGN151 was up to 200 times more active against four FRα-medium cell lines. Furthermore, IMGN151 had also notably stronger bystander killing activity in a mixed culture of target-positive and negative cells. In in vivo studies, IMGN151 induced complete tumor regressions of human tumor xenograft models with high (KB, H-score of 300), medium (Igrov-1 and Ishikawa, H-score of 140 and 100, respectively) and low (Ov-90, H-score of 30) FRα expression. All tested doses were well tolerated with no body weight loss observed. Currently the drug is in Phase I stage of Clinical trial evaluation for the treatment of Endometrial Cancer.
- Daiichi Sankyo
Daiichi Sankyo is dedicated to creating new modalities and innovative medicines by leveraging the world class science and technology for the purpose “to contribute to the enrichment of quality of life around the world.” In addition to the current portfolio of medicines for cancer and cardiovascular disease, Daiichi Sankyo is primarily focused on developing novel therapies for people with cancer as well as other diseases with high unmet medical needs. With more than 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 16,000 employees around the world draw upon a rich legacy of innovation to realize our 2030 Vision to become an “Innovative Global Healthcare Company Contributing to the Sustainable Development of Society.”
- DS-6000
DS-6000 is an investigational potential first-in-class CDH6 directed ADC and one of five ADCs in clinical development in the oncology pipeline of Daiichi Sankyo. Designed using Daiichi Sankyo’s proprietary DXd ADC technology, DS-6000 is comprised of a humanized anti-CDH6 IgG1 monoclonal antibody attached to a number of topoisomerase I inhibitor payloads (an exatecan derivative, DXd) via tetrapeptide-based cleavable linkers. Daiichi Sankyo is developing DS-6000 through a strategic collaboration with Sarah Cannon Research Institute with study operational oversight and delivery provided through Sarah Cannon’s early phase oncology clinical research organization, Sarah Cannon Development Innovationsin Nashville, TN. CDH6 (human cadherin-6) is a cadherin family protein overexpressed in several cancers, particularly ovarian tumors and renal cell carcinoma. Overexpression of CDH6 is associated with tumor growth and proliferation and is correlated with poor prognosis in patients with renal cell carcinoma. No CDH6 directed cancer therapies are currently approved for treatment of any cancer. Currently, the drug is in the Phase I stage of its development for the treatment of Solid tumors.
Gain strategic intelligence on Antibody Drug Conjugate Emerging Therapies, pipeline highlights, and competitive trends shaping the market @ Antibody Drug Conjugate Preclinical and Discovery Stage Products
Antibody Drug Conjugate: Analytical Perspective by DelveInsight
In-depth Commercial Assessment: Antibody Drug Conjugate: Collaboration Analysis by Companies
The Report provides in-depth commercial assessment of ADC drugs that have been included, which comprises collaboration, agreement, licensing and acquisition – deals values trends. The sub-segmentation is described in the report which provide company-company collaboration (licensing/partnering), company academic collaboration and acquisition analysis in tabulated form.
Antibody Drug Conjugate Competitive Landscape
The Antibody Drug Conjugate report comprises of comparative assessment of Antibody Drug Conjugate Companies (by therapy, development stage, and technology).
Antibody Drug Conjugate Report Assessment
- Antibody Drug Conjugate Company Analysis
- Antibody Drug Conjugate Therapeutic Assessment
- Antibody Drug Conjugate Pipeline Assessment
- Inactive Antibody Drug Conjugate drugs assessment
- Antibody Drug Conjugate Unmet Needs
Stay informed on the latest advancements in Antibody Drug Conjugate Research and development—Download the in-depth pipeline and competitive landscape report @ Antibody Drug Conjugate Market Drivers and Barriers
Scope of the Antibody Drug Conjugate Competitive Landscape Report
- Coverage- Global
- Antibody Drug Conjugate Companies- NBE-Therapeutics, ImmunoGen, Inc., Seagen Inc., ADC Therapeutics, Mythic Therapeutics, Sutro Biopharma, Merck KGaA, Sorrento Therapeutics, Inc., Peak Bio, Regeneron Pharmaceuticals, Asana BioSciences, Tanabe Research Laboratories USA, OBI Pharma, Sanofi, and Navrogen, and others.
- Antibody Drug Conjugate Pipeline Therapies- Sacituzumab govitecan, STI-6129, Taxotere (docetaxel), DS-8201a, REGN5093-M114, Cemiplimab, Sacituzumab Govitecan-hziy, M9140, Talazoparib, LCB84 and others.
- Antibody Drug Conjugate Marketed Therapies and Pipeline Therapies
- Antibody Drug Conjugate Preclinical and Discovery Stage Products, Unmet Needs
Understand the Antibody Drug Conjugate Companies, drugs, and market dynamics driving the Antibody Drug Conjugate Pipeline in 2025—Request your copy of the report now @ Antibody Drug Conjugate Mechanism of Action and Unmet Needs
Table of Content
- Introduction
- Executive Summary
- Antibody Drug Conjugate Overview
- Antibody Drug Conjugate-Analytical Perspective: In-depth Commercial Assessment
- Competitive Landscape
- Therapeutic Assessment
- Antibody Drug Conjugate: Company and Product Profiles (Marketed Therapies)
- Pfizer
- MYLOTARG
- Antibody Drug Conjugate: Company and Product Profiles (Pipeline Therapies)
- Late Stage Products (Phase III)
- ADC Therapeutics
- Zynlonta
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Seagen Inc.
- Ladiratuzumab Vedotin
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- ImmunoGen, Inc.
- IMGN151
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Company Name
- Product Name
- Drug profiles in the detailed report…..
- Inactive Products
- Antibody Drug Conjugate – Unmet needs
- Antibody Drug Conjugate– Market drivers and barriers
- Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/antibody-drug-conjugate-competitive-landscape